​​Identifying High-Priority Diagnostic Approaches for Advancing Hepatitis C Elimination in the US

Broadcast in October 2021, this consultation was brought to you by APHL in coordination with the CDC's Division of Viral Hepatitis (DVH).

This meeting was designed to examine and identify the highest-priority diagnostic tools needed to advance hepatitis C elimination in the United States over the next five years. Recordings and presentations are available below.  

Meeting Report

As an outcome of the meeting, APHL has published a draft report which is being made public for a six-week comment period (May 31-July 12, 2022). Once the comment period closes APHL will review the submitted comments and update the document as needed to ensure the meeting report is accurate. General comments will be reviewed and shared with CDC's DVH for their awareness. Please review the meeting summary report (draft) and submit comments (using button below) to APHL by July 12, 2022. When submitting your comments please reference page numbers and line numbers so that we can ensure we are addressing the correct items. The final meeting report will be posted no later than September 2022. 

Meeting Summary Report (Draft) 

Submit Com​ments​

Meeting Recordings​

​The topics are listed below and those presentations with links have been authorized to be posted on this website. Duplication is not authorized without the express written permission of the aut​hors.

Day 1 │ October 19, 2021

Welcome from NCHHSTP Director

Jonathan "Jono" ​​Mermin, MD, MPH, CDC

Opening Session

Key Question 1: What HCV diagnostic tools are needed to optimize diagnosis of current HCV infection in moderate to high volume laboratories performing moderate or high complexity testing?​ 

  • Moderator: Michael P. Busch, MD, PhD, Vitalant Research Institute, University of ​California—San Fransisco
  • Presenter: Joseph D. Yao, MD, Mayo Clinic, Mayo Clinic Laboratories
  • Panelists: 
    • Lesley Miller, MD,​ Grady Liver Clinic, Emory University
    • Monica Parker, PhD, Wadsworth Center, NY State Department of Health 
    • Liisa Randall, PhD, Massachusetts Department of Public Health

Key Question 2: What HCV diagnostic tools are needed to advance diagnosis of current HCV infection in low volume settings performing moderate complexity laboratory testing or CLIA-waived testing in clinical settings?

  • ​Moderator: Tanya Applegate, PhD, Kirby Institute
  • Presenter: Stacey Trooskin, MD PhD, Philadelphia FIGHT Community Health Centers
  • Panelists: 
    • William Meyer III, PhD, D(ABMM), MLS(ASCP)CM, Quest Diagnostics
    • Arthur Kim, MD, Massachusetts General Hospital, Harvard Medical School
    • Biz McChesney, Iowa Department of Public Health

Day 2 │ October 20, 2021

Key Question 3: What HCV diagnostic tools are needed to advance diagnosis of current HCV infection in outreach settings and  self-testing in a non-clinical setting?

  • ​Moderator: Judith Feinberg, MD, West Virginia University
  • Presenter: Kimberly Page, PhD, MPH, MS, University of New Mexico
  • Panelists: 
    • Colleen Flanigan, RN, MS, New York State Department of Health
    • Marty Soehnlen, PhD, MPH, PHLD(ABB), Michigan Public Health Laboratory
    • Lynn E. Taylor, MD, CODAC Behavioral Health, University of Rhode Island

Key Question 4: What other tools are needed to support same-day diagnosis and treatment of current HCV infection?

  • ​Moderator: John Ward, MD, Task Force for Global Health
  • Presenter: Raymond Chung, MD, Mass General Hospital, Harvard Medical School
  • Panelists: 
    • Marc Ghany, MD, MHSc, National Institutes of Health
    • Jorge Mera, MD, Cherokee Nation Health Services
    • Benjamin Pinsky, MD, PhD, Stanford University School of Medicine​